Neonc Technologies Holdings Expects Full Enrollment In Promising Phase 2A Trial Of Neo100-01 For Malignant Gliomas In September
April 14 (Reuters) - Neonc Technologies Holdings Inc NTHI.O:
NEONC TECHNOLOGIES HOLDINGS, INC. EXPECTS FULL ENROLLMENT IN PROMISING PHASE 2A TRIAL OF NEO100-01 FOR MALIGNANT GLIOMAS IN SEPTEMBER
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Microsoft 2026 Q3 Earnings Preview: Can Azure’s Growth Momentum Keep Up With Massive AI Capital Spending?

Marvell vs. Broadcom: Who Is the More Worthy ASIC Leading Company?

Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

SanDisk Earnings Preview: AI Storage Drives Performance Surge, Valuations and Risks Rise

Tradingkey







